Mp74-03 Superiority of Midlife Baseline Prostate-Specific Antigen Value Over Psa Doubling Time and Velocity in the Prediction of Lethal Prostate Cancer Development, and Mortality: A System Wide Analysis of a Racially Diverse North American Cohort

You have accessJournal of UrologyProstate Cancer: Detection 0.749 and 0.708 at 10- and 15-year, respectively, for the PSAV and 0.840 and 0.750 at 10- and 15-year, respectively, for the MB PSA (all p>0.05). CONCLUSIONS: Our findings are that PSAV or PSADT were not superior to midlife baseline PSA in predicting the development of lethal PCa. This suggests that these variables may not have practical utility in enhancing PSA screening strategies in a clinical setting. Source of Funding: Vattikuti foundation and Menon foundation © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1193 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Matthew Davis More articles by this author Giuseppe O. Cirulli More articles by this author Alex Stephens More articles by this author Giuseppe Chiarelli More articles by this author Marco Finati More articles by this author Chase Morrison More articles by this author Shane Tinsley More articles by this author Sohrab Arora More articles by this author Akshay Sood More articles by this author Nicolò Buffi More articles by this author Giovanni Lughezzani More articles by this author Giuseppe Carrieri More articles by this author Andrea Salonia More articles by this author Alberto Briganti More articles by this author Francesco Montorsi More articles by this author Craig Rogers More articles by this author Firas Abdollah More articles by this author Expand All Advertisement PDF downloadLoading ...